TZ 30mg (TZP) – 99% Purity Crystalline Powder Vial, CAS 2023788-19-2

What is TZP 30mg?

TZ 30mg refers to TZP 30mg, a synthetic research peptide (often supplied as lyophilized powder in a 30mg vial) commonly abbreviated as TZ, TZP, or Tirz in scientific and research contexts. It is a dual agonist peptide designed for laboratory investigation into metabolic pathways, glucose regulation, and related mechanisms.

This compound is provided strictly for in vitro, preclinical, or experimental research purposes (e.g., cell culture studies, animal models, or mechanistic analyses) and is not intended for human therapeutic use.

Basic Information of TZP 30mg

Key Features:

• Dual receptor agonist: Activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, enabling synergistic effects in metabolic signaling pathways.
• Synthetic structure: A 39-amino acid linear peptide analog with lipidation (e.g., C20 fatty diacid moiety) for enhanced stability, prolonged half-life, and albumin binding in experimental systems.
• High purity format: Typically supplied as ≥98-99% pure lyophilized (freeze-dried) powder in sealed vials for stability, easy reconstitution, and long-term storage in research settings.
• Once-weekly dosing potential in models: Due to its pharmacokinetic profile (extended half-life ~5 days), suitable for studies simulating intermittent administration.

Research Applications:

Researchers utilize TZ in controlled laboratory and preclinical studies to explore:

• Glucose homeostasis and insulin secretion mechanisms (e.g., glucose-dependent insulin release from pancreatic beta cells, glucagon modulation).
• Appetite regulation, satiety signaling, and energy balance pathways in metabolic models.
• Weight management and body composition dynamics, including reductions in fat mass and improvements in lipid profiles.
• Glycemic control in models of type 2 diabetes-like conditions (e.g., HbA1c/A1C reduction analogs, insulin sensitivity enhancement).
• Potential downstream effects on cardiorenal systems, inflammation, and ectopic lipid accumulation in relevant experimental tissues.
• Synergistic incretin pathway interactions compared to single GLP-1 agonists.

Product Photos